Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights
Meningiomas are the most common primary intracranial tumors, with TRAF7 mutations identified in ~25% of cases. These mutations, associated with NFκB pathway activation, are linked to higher recurrence rates than other low-grade-associated mutations. We report a 49-year-old Caucasian woman with recur...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251363340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699854570225664 |
|---|---|
| author | Emily Pack Sonikpreet Aulakh |
| author_facet | Emily Pack Sonikpreet Aulakh |
| author_sort | Emily Pack |
| collection | DOAJ |
| description | Meningiomas are the most common primary intracranial tumors, with TRAF7 mutations identified in ~25% of cases. These mutations, associated with NFκB pathway activation, are linked to higher recurrence rates than other low-grade-associated mutations. We report a 49-year-old Caucasian woman with recurrent TRAF7-mutated World Health Organization Grade 2 meningiomas. Initially diagnosed with World Health Organization Grade 1 meningiomas in 2015, her disease progressed to Grade 2 chordoid meningioma by 2021. Molecular profiling revealed a TRAF7 exon 20 (p.R653Q) mutation and PMS2 deletion. Multiple surgical resections, radiation, and systemic therapies, including lanreotide, bevacizumab, and pembrolizumab, were employed, with pembrolizumab showing a favorable response due to mismatch repair deficiency. This case highlights the molecular and histological evolution of TRAF7-mutated meningiomas and the potential of immunotherapy in recurrent cases. The absence of targeted therapies for TRAF7-positive tumors underscores the need for mutation-specific clinical trials. |
| format | Article |
| id | doaj-art-4e6f5e12dd4e4ae3831037dead2618d4 |
| institution | DOAJ |
| issn | 2050-313X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj-art-4e6f5e12dd4e4ae3831037dead2618d42025-08-20T03:18:27ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-08-011310.1177/2050313X251363340Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insightsEmily Pack0Sonikpreet Aulakh1West Virginia University School of Medicine, Morgantown, WV, USADepartment of Medical Oncology, West Virginia University, Morgantown, WV, USAMeningiomas are the most common primary intracranial tumors, with TRAF7 mutations identified in ~25% of cases. These mutations, associated with NFκB pathway activation, are linked to higher recurrence rates than other low-grade-associated mutations. We report a 49-year-old Caucasian woman with recurrent TRAF7-mutated World Health Organization Grade 2 meningiomas. Initially diagnosed with World Health Organization Grade 1 meningiomas in 2015, her disease progressed to Grade 2 chordoid meningioma by 2021. Molecular profiling revealed a TRAF7 exon 20 (p.R653Q) mutation and PMS2 deletion. Multiple surgical resections, radiation, and systemic therapies, including lanreotide, bevacizumab, and pembrolizumab, were employed, with pembrolizumab showing a favorable response due to mismatch repair deficiency. This case highlights the molecular and histological evolution of TRAF7-mutated meningiomas and the potential of immunotherapy in recurrent cases. The absence of targeted therapies for TRAF7-positive tumors underscores the need for mutation-specific clinical trials.https://doi.org/10.1177/2050313X251363340 |
| spellingShingle | Emily Pack Sonikpreet Aulakh Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights SAGE Open Medical Case Reports |
| title | Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights |
| title_full | Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights |
| title_fullStr | Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights |
| title_full_unstemmed | Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights |
| title_short | Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights |
| title_sort | recurrent traf7 mutated meningioma molecular evolution and therapeutic insights |
| url | https://doi.org/10.1177/2050313X251363340 |
| work_keys_str_mv | AT emilypack recurrenttraf7mutatedmeningiomamolecularevolutionandtherapeuticinsights AT sonikpreetaulakh recurrenttraf7mutatedmeningiomamolecularevolutionandtherapeuticinsights |